LIFE: Lifecare ASA Q3 2026 results
Bergen, Norway, 12 November 2026: Today, Lifecare ASA (LIFE), a medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes its Q3 2026 financial report and operational update.
Highlights:
- First functional CGM implants successfully manufactured at Lifecare’s facilities in Bergen
- Subsequent production batches demonstrate encouraging progress towards repeatable manufacturing processes
- Acquisition of Ocean TuniCell provides established laboratory and cleanroom infrastructure, specialised equipment and biological and laboratory expertise in Bergen
- Scientific development expands the opportunity for Lifecare’s osmotic sensing technology beyond glucose, while CGM remains the primary operational priority
- The operational restructuring initiated in Q1 2026 has materially reduced the Company’s cost base. The operating loss for Q3 2026 was NOK 12.2 million, compared with NOK 65.9 million in Q3 2025, reflecting a more focused operating model
- Cash position of NOK 30.3 million at quarter end, with the current operating plan expected to provide runway into Q2 2027
During the third quarter, Lifecare achieved a significant operational milestone by successfully manufacturing its first functional CGM implants at the Company’s facilities in Bergen. Subsequent manufacturing runs and batches in October have demonstrated encouraging progress towards establishing repeatable production processes.
“This gives us a substantially stronger foundation for systematic product testing, process optimisation and the generation of the evidence required for clinical and regulatory development,” says Lifecare CEO Joacim Holter.
The acquisition of Ocean TuniCell provides a faster and more capital-efficient route towards developing Lifecare’s controlled manufacturing capabilities than establishing equivalent infrastructure independently. Ocean TuniCell also adds a proprietary nanofibrillar cellulose technology platform with independent scientific and commercial opportunities.
“The acquisition of Ocean TuniCell had an immediate positive effect on our operations. Progressing Lifecare’s manufacturing and engineering, combined with the biological expertise, testing and infrastructure capabilities of Ocean TuniCell, significantly strengthen our execution capacity in Bergen,” Holter says.
Lifecare’s immediate priority remains to establish reproducible, controlled manufacturing and complete the verification and documentation required for the planned pivotal CE-mark clinical investigation.
Results presentation
CEO Joacim Holter and CFO Petter Nielsen will present the Q3 results on webcast today at 10:00 CET.
To access the webcast join the meeting here.
A recording of the webcast will be available on our website after the event.